Use of Angiotensin System Inhibitors Is Associated With Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-0256
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

EGFR, but Not COX‑2, Protein in Resected Pancreatic Ductal Adenocarcinoma Is Associated With Poor Survival

Oncology Letters
Cancer ResearchOncology
2019English

Increased CDC20 Expression Is Associated With Pancreatic Ductal Adenocarcinoma Differentiation and Progression

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2012English

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

Elevated McP-1 Is Associated With Cancer Cachexia in Patients With Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2017English

Infiltrating Immune Cells and Gene Mutations in Pancreatic Ductal Adenocarcinoma

British Journal of Surgery
Surgery
2016English

Nationwide Trends in Incidence, Treatment and Survival of Pancreatic Ductal Adenocarcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

CCAT2 Is an Oncogenic Long Non-Coding RNA in Pancreatic Ductal Adenocarcinoma

Biological Research
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgricultural
2018English

Switchable CAR-T Cells Mediate Remission in Metastatic Pancreatic Ductal Adenocarcinoma

Gut
Gastroenterology
2018English

Use of Renin-Angiotensin System Inhibitors Is Associated With Reduction of Fracture Risk in Hemodialysis Patients

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy